Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study

Table 1 Baseline patients’ characteristics

	Overall (n = 1289)	4 L PEG (Selgesse®) (n = 490)	2 L PEG (Moviprep® or Clensia®) (n = 566)	1 L PEG (Plenvu®) (n = 233)
Sex, n (%)
Male	681 (52.8)	268 (54.7)	291 (51.4)	122 (52.4)
Female	608 (47.2)	222 (45.3)	275 (48.6)	111 (47.6)
Age, years, mean ± SD	60.5 ± 14.1	61.1 ± 14.1	60.5 ± 13.5	59.5 ± 15.9
Age group, n (%)
< 65 yr	708 (55.2)	259 (53.1)	318 (56.5)	131 (56.5)
≥ 65 yr	575 (44.8)	229 (46.9)	245 (43.5)	101 (43.5)
Race group
White or Caucasian	1254 (97.3%)	479 (97.8%)	550 (97.2%)	225 (96.6%)
Other	35 (2.7%)	11 (2.2%)	16 (2.8%)	8 (3.4%)
Weight, kg, mean ± SD	72.3 ± 14.6	73.3 ± 14.4	72.0 ± 15.4	71.1 ± 13.0
Height, cm, mean ± SD	165.8 ± 9.0	165.9 ± 9.8	165.6 ± 8.5	166.3 ± 8.7
BMI, mean ± SD	26.2 ± 4.6	26.6 ± 4.6	26.2 ± 4.9	25.6 ± 4.0
Obesity	236 (18.3%)	101 (20.6%)	105 (18.6%)	30 (12.9%)
Chronic constipation	215 (16.7%)	84 (17.1%)	101 (17.8%)	30 (12.9%)
Diabetes	144 (11.2%)	68 (13.9%)	62 (11.0%)	14 (6.0%)
Hypertension	492 (38.2%)	218 (44.5%)	223 (39.4%)	51 (21.9%)
Chronic renal failure	30 (2.3%)	11 (2.2%)	12 (2.1%)	7 (3.0%)
Colonoscopy indication, n (%)
Screening	443 (34.4%)	159 (32.5%)	201 (35.5%)	83 (35.6%)
Surveillance	303 (23.5%)	128 (26.1%)	121 (21.4%)	54 (23.2%)
Diagnostic	543 (42.1%)	203 (41.4%)	244 (43.1%)	96 (41.2%)

PEG: Polyethylene glycol.